Bank of America Initiates MiniMed Coverage with Buy Rating and $27 Target

Key Facts

1Bank of America initiated coverage on MiniMed Group (NASDAQ: MMED) with a 'Buy' rating and a $27 price target.

2The price target implies an upside of approximately 100% from the current level of about $14.

3Analysts view the company as reaching a key inflection point following its recent separation from Medtronic.

Bank of America has initiated coverage on MiniMed Group (NASDAQ: MMED) with a "Buy" rating and a price target of $27 per share. This target implies a significant upside potential of approximately 100% from the stock's current trading price of about $14. Analysts at the bank believe the diabetes management technology specialist has reached a critical inflection point in its business cycle. The positive outlook follows MiniMed's recent strategic separation from Medtronic, which is expected to streamline its operations and focus. Furthermore, the report emphasizes the company's robust growth pipeline and its strengthened position within the medtech sector. Such a bullish initiation from a top-tier investment bank typically generates increased investor interest and upward momentum for the equity in the near term.